囊泡谷氨酸转运体与阿尔茨海默病  

Vesicle glutamate transporters and Alzheimer′s disease

作　　者：王静 程肖蕊[2] 周文霞[1,2] 王淑美[1] 

机构地区：[1]广东药科大学中药学院,广州510006 [2]军事医学科学院毒物药物研究所,抗毒药物与毒理学国家重点实验室,中药与神经免疫药理研究室,北京100850

出　　处：《国际药学研究杂志》2016年第2期191-198,共8页Journal of International Pharmaceutical Research

基　　金：国家自然科学基金资助项目(81473191;30973541)

摘　　要：囊泡谷氨酸转运体(VGLUT)决定脑中谷氨酸装载进入囊泡的数量及释放,进而调节神经传导的效率,在阿尔茨海默病(AD)的发病机制中发挥重要作用。VGLUT在AD脑中减少,与AD的认知功能障碍、β淀粉样蛋白(Aβ)聚集、tau蛋白过度磷酸化以及谷氨酸兴奋性毒性密切相关,可能作为AD早期警示性的分子,也有可能成为防治AD的药物靶点,且以VGLUT为靶点的药物研发也取得了一些进展。Vesicle glutamate transporter（VGLUT） specifically transfers glutamate into synaptic vesicle,determines the amount of glutamate released into the synaptic cleft,then regulates the efficiency of glutamatergic synaptic transmission. VGLUT plays an important role in the pathogenesis of Alzheimer′s diseases（AD）. VGLUT is significantly decreased in the brain of AD patients and closely correlated with cognitive dysfunction,beta- amyloid aggregation,tau protein phosphorylation and glutamate excitoxicity.VGLUT,the possible specific biomarker of glutamatergic neuron,has been considered a potential drug target in the treatment of AD and biomarkers in the early diagnosis of AD. There are some advances on chemicals targeting on VGLUT.

关 键 词：阿尔茨海默病 囊泡谷氨酸转运体 Β-淀粉样蛋白 神经原纤维缠结 兴奋性毒性 

分 类 号：R749.16[医药卫生—神经病学与精神病学]